Brief: IN8bio Provides INB-200 Clinical Update And Outlines 2023 Pipeline Goals
05/01/2023 12:19
Jan 5 (Reuters) - IN8BIO, Inc. INAB.O :
* IN8BIO PROVIDES INB-200 CLINICAL UPDATE AND OUTLINES 2023
PIPELINE GOALS
* IN8BIO, INC. - SUBMISSION OF INVESTIGATIONAL NEW DRUG
APPLICATION (IND) FOR PHASE 1B TRIAL OF INB-410 ANTICIPATED IN
2H 2023
Source text for Eikon: ID:nGNX7Sz8zC
Further company coverage: INAB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IN8bio
See all newsIN8bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Biopharma firm IN8bio's Q2 net loss narrows as expenses decline
IN8bio Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: IN8BIO - Enters Capital On Demand Sales Agreement With Jonestrading For ATM Offering
IN8bio Q1 net loss narrows as R&D expenses fall